Newswise — HOUSTON & POHANG, South Korea – The University of Texas MD Anderson Cancer Center and C-Biomex Ltd. today announced a strategic research collaboration agreement to co-develop CBT-001,…
Read more MD Anderson and C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapySubcutaneous formula slashes treatment time to under 5 minutes Broad impact seen for greater access to and experience with treatment Study has implications for treatment of many cancer…
Read more Subcutaneous Nivolumab as Effective as IV for Renal Cell Carcinoma — With Much Faster Treatment TimeNewswise — A new study led by Yale Cancer Center researchers at Yale School of Medicine revealed a significant increase in patients starting immunotherapy within one month of…
Read more Patients Less Likely to Experience Death at Academic and High-Volume Hospitals When Treated with Immunotherapy for Metastatic CancersNewswise — SAN DIEGO ― Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of…
Read more ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosisNewswise — SAN DIEGO ― The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood…
Read more ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorderNewswise — Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of…
Read more ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemiasNewswise — HOUSTON ― The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Data Science in Oncology (IDSO), which integrates the…
Read more MD Anderson announces Institute for Data Science in Oncology to advance mission to end cancerNewswise — New York, October 27, 2023 The Cancer Research Institute (CRI), a nonprofit organization dedicated to harnessing the immune system’s power to control and potentially cure all…
Read more Cancer Research Institute to Honor Dr. Ananda Goldrath with 2023 Alt AwardNewswise — Boston – A drug that simultaneously strikes cancer cells’ growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with…
Read more Dual-action drug produces positive results in patients with advanced neuroendocrine tumors, trial findsNewswise — MADRID ― Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with…
Read more ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancerNewswise — Boston – Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously…
Read more Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimusNewswise — SINGAPORE ― Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as it reduces radiation…
Read more Intensity-modulated radiation therapy provides long-term benefits to patients with locally advanced lung cancerNewswise — Treatment planning for lung cancer can often be complex due to variations in assessing immune biomarkers. In a new study, Yale Cancer Center researchers at Yale…
Read more AI more accurately identifies patients with advanced lung cancer that respond to immunotherapy and helps doctors select treatmentsNewswise — Although immunotherapies have shown promise in treating non-small cell lung cancer (NSCLC), many patients still do not respond well, and those who do may eventually develop…
Read more New immunotherapy treatment brings hope to patients with advanced non-small cell lung cancerNewswise — HOUSTON and SAN MATEO, Calif. ― The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a…
Read more MD Anderson and Panacea launch Manaolana Oncology to develop antibody-based therapies for cancerThe image on the left shows raw data, and the image on the right shows how SparkMaster 2 detects calcium sparks, miniwaves and waves. (SACRAMENTO) A team of…
Read more Software developed at UC Davis analyzes calcium ‘sparks’ that can contribute to arrhythmiaNewswise — Boston – The Pancreatic Cancer Action Network (PanCAN), a leading non-profit in the fight against pancreatic cancer, has awarded Dana-Farber Cancer Institute researchers William Freed-Pastor, MD,…
Read more Pancreatic cancer research in vaccines, immune-based therapies and KRAS inhibition funded by The Pancreatic Cancer Action NetworkNewswise — (SACRAMENTO, Calif.) — Ophthalmologists at UC Davis Health used an experimental gene therapy last month to treat a patient with wet age-related macular degeneration, or wet AMD.…
Read more UC Davis Eye Center tests experimental gene therapy for wet age-related macular degeneration (AMD)Newswise — New Brunswick, N.J., August 14, 2023 – Researchers at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School (NJMS), together with other collaborating groups,…
Read more Rutgers Researchers Identify Lipid Vascular ‘ZIP code’Newswise — PLYMOUTH MEETING, PA [August 9, 2023] — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced new grants awarded to improve quality initiatives…
Read more NCCN Announces Research Funding for Biomarker-Directed Therapy in Metastatic Colorectal Cancer, in Collaboration with Fight CRC and Pfizer
